The global familial adenomatous polyposis treatment market is anticipated to grow at a significant CAGR of 13.9 % during the forecast period. FAP is a hereditary condition. Emerging drugs such as eRapa is expected to boost the market growth over the forecast. The eRapa (encapsulated rapamycin) is a patented, micro-encapsulated formulation of Rapamycin that protects the active ingredient from...